We are happy to announce our new report is launched: "Ukraine Pharmaceutical & Healthcare Industries Overview 2018". The report includes Ukrainian economic, pharmaceutical and healthcare latest trends in a tailored made systematic and business styled manner. The Overview was developed for decision-makers and industry professionals, life sciences stakeholders globally. It covers the 2012-2017 FY historical data with the forecast of the economics and pharmaceutical market numbers to 2018-2019.
|Report name:||Pharmaceutical and Healthcare Industries Overview 2018|
|How to buy:||Buy by Invoice|
Ukraine Pharmaceutical & Healthcare Industries Overview 2018 provides an essential information about the Ukrainian pharmaceutical market its healthcare landscape, macroeconomic situation and more, including:
REASONS TO BUY THE OVERVIEW
This report will enhance your view of the Ukrainian pharmaceutical market, its healthcare environment by making you possible to:
This article is based on the "Ukraine Pharmaceutical and Healthcare Industries Overview 2018" report prepared by UPharma Consulting and contains short excerpts from this report.
In 2017 the government doubled minimal salaries, which stimulated higher-than-expected inflation. Ukraine failed to achieve a 3% GDP growth goal in 2017 mainly due to announced transport blockade of the occupied territories of Donetsk and Lugansk regions, which damaged Ukrainian enterprises. The slowdown in the growth of the economy was accompanied by the deterioration of Ukraine’s relations with Western creditors, which, despite the completion of the current financial support programs, don’t hurry to give Kyiv new aid, demanding to strengthen the fight against corruption.
The Ukrainian government took big efforts to improve the business climate, but the country climbed only by 4 positions in the Doing Business 2018 rating to 76th position. Foreign investors reduced investments in the country from USD 4.4 bn in 2016 to USD 2.5 bn in 2017.
In Q3 2017, Ukraine’s economy grew 2.1% y-o-y, down slightly from 2.3% in Q2 and 2.5% in Q1. The last quarter of the year showed the worst growth dynamics, but an improving service sector remained strong enough to compensate for a significant drop in agriculture and industry. According to a provisional estimate of the NBU, Ukraine’s 2017 GDP grew 2.1% y-o-y.
Russian military aggression, the macroeconomic crisis and worsening of households’ well-being as well as and the high level of youth unemployment caused a significant increase in labor migration both internal and external. It was accelerated after the introduction of the visa-free regime with the EU in June 2017. According to the polls, the poverty rate decreased by 5% to 12% in 2017 after it almost doubled from 2014 to 2016.
The commodity supply chain of the pharmaceutical industry in the country includes foreign companies (imported products), local manufacturers, wholesalers/distributors of pharma related products, public and private hospitals, and the retail segment. All of the segments have different levels of consolidation, margin levels and other peculiarities. There are no vertical integrated holdings within the industry. Standard pharmacy assortment in Ukraine comprises four categories: pharmaceuticals, medical devices, food supplements and cosmetics. The pharmaceutical market of Ukraine is conventionally divided into retail and hospital segments.
In 2017 the total pharmaceutical market grew by almost +16% vs. 2016 to $3 billion and by +6.5% - in volumes to 1,794 mio units. The sales Rx drugs notably grew in resent years making this segment the main driver of the market growth.
As on the beginning of 2018, there were almost 20.5 thousand retail point of sales in Ukraine, which consisted of pharmacies (79.1%) and pharmacy units (20.9%). In Ukraine pharmacy chains classified by the number of pharmacies in the structure and by the territory, where they carry out the economic activity. The number of points of sales of pharmaceuticals is gradually increasing, mainly due to opening of new pharmacies on the background of gradual reduction in the number of pharmacy units.
Pharmaceutical & Healthcare Industries Overview 2017/2018 - is a professional industry report, which covers crucial economic, pharmaceutical and healthcare information for decision makers and industry professionals globally. The Overview will be useful for top-managers, business owners, consultants and other stakeholders of the Life Sciences industry, who analyze, plan entering or investing into the one of the CIS pharma markets.
For additional information, please, contact, Eugene Brovko via email firstname.lastname@example.org or phone +380 (98) 224-98-64